

## Joint Technical Work Group

### WORK GROUP RECAPS

May 2024

For results of Data Element Request Forms (DERFs) and External Code List (ECLs) reviewed see DERF Resolution at <https://member.ncpdp.org/work-groups.aspx?ID=wgmc>.

### Work Group 1 Telecommunication

#### Ballots:

- **Ballot WG010091** – Enhancements to the Batch Standard Subrogation Implementation Guide Version 11 is considered a valid ballot having received the required 60+% of Consensus Group votes and 75+% approval rating. Two affirmative votes with comments were received. WG1 reviewed and categorized the comments as persuasive and editorial. See Letter Ballot Comment spreadsheet for the ballot results and categorization of comments with reasons on the WG1 webpage. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.
- **Ballot WG010092** – Enhancements to the Benefit Integration Standard Implementation Guide Version 19 is considered a valid ballot having received the required 60+% of Consensus Group votes and 75+% approval rating. No comments were received. See Letter Ballot Comment spreadsheet for the ballot results on the WG1 webpage. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.

#### DERFs Reviewed:

- DERF 001991/ECL 000418 was recommended to MC to approve as modified.
- DERF 001992/ECL 000419 was recommended to MC to approve as modified.
- DERF 002004/ECL 000422 was recommended to MC to approve.
- DERF 002005/ECL 000423 was recommended to MC to approve.
- DERF 002006/ECL 000424 was recommended to MC to approve as modified.
- DERF 002007/ECL 000425 was recommended to MC to approve.
- DERF 002008/Emergency ECL 000426 was recommended to MC to pend.
- DERF 002009/ECL 000427 was recommended to MC to pend.
- DERF 002010/ECL 000428 was recommended to MC to pend.
- DERF 002011/ECL 000429 was recommended to MC to approve as modified.
- DERF 002012/Emergency ECL 000430 was recommended to MC to approve as modified.
- DERF 002013/Emergency ECL 000431 was recommended to MC to approve.
- DERF 002014/ECL 000432 was recommended to MC to approve.
- DERF 002015/ECL 000433 was recommended to MC to approve.
- DERF 002016/Emergency ECL 000434 was withdrawn.
- DERF 002017/Emergency ECL 000435 was recommended to MC to pend.

#### Task Groups:

- The **Telecommunication FAQ Task Group** reviewed six DERFs and discussed several topics such as:
  - Transition from US government supplied product to commercially available product for COVID-19 anti-virals.
  - Telecommunication Standard Version F6 definitions for transmission and transaction level segments.

- Prescriber validation reject codes.
- Pricing impacts from the use of Additional Message Information Qualifier value 36 – *POS Maximum Pharmacy Price Concession*.
- A request for a claim indicator to note a claim is not eligible for drug rebates from the manufacturer.
- Benefit synchronization transaction updates to the Benefit Integration Standard.
- A WG9 Insulin Pump Sub-Task Group proposal to use a DUR value to indicate how insulin is administered for appropriate billing to Medicare.
- FAQs about the Medicare Prescription Payment Plan to be published in the *Medicare Part D Frequently Asked Questions*.

The task group also received approval for their revised scope and approval to publish an FAQ regarding segments at the transaction and transmission level in the *Telecommunication Version D and Above Questions, Answers and Editorial Updates*.

- The **Adjudicated Program Type Sub-Task Group** began drafting an FAQ and several examples on how and when to use new Adjudicated Program Type-related fields and presented DERF 002004/ECL 000422 for a new value for Federal Employee Health Benefit (FEHB) program and DERF 002005/ECL 000423 to sunset one and create two new Medicare Advantage values. Both DERFs were approved.
- The **P and C/WC Monitoring, Billing and Education Task Group** discussed current Property and Casualty/Workers' Compensation legislative activity.
- The **Coordination of Benefits (COB) Task Group** drafted transition guidance for COB claims when the primary is Telecommunication Standard vD.0 and the secondary is VF6 and for COB claims when the primary is VF6 and the secondary is vD.0 for the three COB billing methods. They also reviewed various COB questions submitted.
- The **Information Reporting Problems Task Group** continued drafting Telecommunication Standard vD.0 to VF6 transition guidance including some potentially troublesome fields and how the Part D Transaction Facilitator should process N transactions during the transition period. The task group recommendation is dependent on CMS accepting a new project plan beginning August 2024. The task group is forming a small group to finish the COB White Paper review.
- The **Definition of a Valid Prescriber Task Group** continued working on prescriber related updates to the *Telecommunication Version D and Above Questions, Answers and Editorial Updates* and refining their Medicaid and Medicare prescriber matrices and flow diagrams. They created a replacement FAQ for Section 6.4.3, FAQ 3 which was approved for publication in the *Telecommunication Version D and Above Questions, Answers and Editorial Updates* and requested a value limitation update to Prescriber ID Qualifier (466-EZ) value 18 in DERF 002008/Emergency ECL 000426, which was pended to **WG19 No Rx OTC Transaction Processing Task Group** for additional discussion. The task group also reviewed the timeliness of CMS Preclusion List updates and publications compared to notifications. CMS was notified of the need to be timelier, and the task group will continue to monitor the situation.
- The **Benefit Integration Task Group** continued their review of the Benefit Integration Implementation Guide, reviewed the layout document and reviewed an ECL DERF for a new Patient Pay Component Qualifier.
- The **Clinical and Safety Edits Task Group** created a DERF and accompanying FAQ to provide recommendations and values for responses returned when coverage of duplicate therapy may be allowed with a limited time restriction. DERF 002006/ECL 000424 and the FAQ, both, were approved as modified. The FAQ will be published in the *Telecommunication Version D and Above Questions, Answers and Editorial Updates*.

- The **Telecommunication Agility Next Generation (TANG) Task Group** did not meet this quarter but will advocate for the DERFs that will revise data structures for the Telecommunication Standard in JSON.
- The **Pharmacy Services Billing Task Group** drafted and reviewed guidance for Section 5 – NCPDP Service Billing Reference Documents, Section 6 – Professional Service Billing Code Options and Recommendations, Section 7 – Claim Response Transactions, Section 8 – Use Cases, Section 9 – Transaction Routing, Section 10 – Payer Sheet and Section 11 – Best Practices/FAQs. The task group also reorganized the document for consistency and improved flow.
- The **Eligibility Verification Enhancements Task Group** is advertising CMS’s request for input on the use of the Medicare Beneficiary ID (MBI) and MBI vulnerabilities in various Medicare Part D processes. Pharmacies are asked to review CMS’s questions that will be uploaded on the Collaborative Workspace after May Work Group meetings and respond by June 14, 2024, to [PartD\\_COB@cms.hhs.gov](mailto:PartD_COB@cms.hhs.gov).
- The **Expanded Dollar Fields Task Group** did not meet this quarter.
- The **Post Adjudication Task Group** did not meet this quarter.
- The **Standardized Subrogation Task Group** worked on transition guidance from Medicaid Subrogation to Batch Standard Subrogation and reviewed SNIP Committee’s drafted Reconciliation ID guidance. The task group also submitted DERF 002007/ECL 000425 requesting a new Basis of Reimbursement Determination (522-FM) value. The DERF was approved.
- The **Universal Claim Form (UCF) Task Group** moved their meeting time to opposite Tuesdays from WG1 Telecommunication FAQ Task Group, received feedback on potential changes to overall structure of the UCF and began identifying necessary updates to the UCF to accommodate the next named version of the Telecommunication Standard under HIPAA. The task group also received work group approval to update their scope.

#### Other Reportables:

- **DSMO Change Request, WG19 Real-Time Prescription Benefit Standard Task Group, WG19 REMS Workflow to Transaction Task Group and SNIP Committee:** Recaps for these topics, task groups and committee can be found in the WG1 download materials.

#### New Business:

- An FAQ for identifying claims with no prescription was presented but was not put forth for a vote.
- The **WG1 2023-2024 Accomplishments** presentation was given.
- NCPDP Telecommunication Standard Version F6 certified members were recognized.

## Work Group 2 Product Identification

#### Ballots:

- **Ballot WG020015** – Enhancements to the Product Identifiers Standards Implementation Guide Version 1.9 is considered a valid ballot having received the required 60+% of Consensus Group votes and 75%+ approval rating. No comments were received. See Letter Ballot Comment spreadsheet for the ballot results on the WG2 webpage. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.

#### DERFs Reviewed:

- DERF 002018 was approved.

#### Task Groups:

- The **Product Review and Billing Unit Exception Task Group** reviewed five QUIC Forms. The task group drafted and submitted DERF 002018 for updates to the Billing Unit Standard (BUS) Implementation Guide which is now maintained under continuous maintenance. The DERF was

approved. Additionally, the task group sent a letter to Merck explaining the issues with re-using NDC numbers.

- The **Naming Standards for Drugs, Biologics and Biosimilars Task Group** met with Gillian Woollett, Vice President of Samsung Bioepis US (SBUS) Regulatory Strategy and Policy, to share perspectives about recent developments within the Food and Drug Administration (FDA) concerning biosimilars and interchangeable biosimilars. Additionally, the task group continued to discuss the FDA's September 2023 draft guidance to the industry on *Labeling for Biosimilar and Interchangeable Biosimilar Products* as well as FDA's recent systematic review and meta-analysis that found no difference in safety outcomes or immunogenicity when switching between reference biologics and their biosimilar products.
- The **Dates Associated with Pharmaceutical Products Task Group** completed reviewing the *Dates Associated with Pharmaceutical Products* white paper and incorporated the recommended changes, including the FDA certification date. Final updates will be made and presented for approval at the August 2024 Work Group.

Other Reportables:

- **WG19 REMS Workflow to Transaction Task Group, WG19 NDC Scarcity Task Group and WG19 Digital Therapeutics Task Group:** Recaps for these task groups can be found in the WG2 download materials.
- Tammy Powell of National Library of Medicine (NLM) provided an update on RxNorm and DailyMed.

New Business:

- New QUIC Form Review:
  - QUIC #202402 Ojemda™ (Tovorafenib)  
**WG2 approved assignment of BU = ML per section 5.2.3 of the BUS with a package size of 12 mL for NDC 51167-290-09.**
  - QUIC #202403 Abrilada™ Prefilled PEN  
**WG2 approved assignment of BU = EA per section 5.5.1, 5.6, 7.4 and 7.5 of the BUS with a package size of 1 EA (kit) for NDCs 0069-0325-02 and 0025-0325-02.**
  - QUIC #202404 Fidanacogene elaparvovec  
**WG2 approved assignment of BU = EA per 5.1.7 of the BUS with a package size of 1 EA for NDC 0069-0422-01 (inner NDC) and a package size of 1 EA for (outer carton) NDC numbers 0069-2004-04, 0069-2005-05, 0069-2006-06 and 0069-2007-07.**
  - QUIC #202405 Formoterol with Nebulizer  
**WG2 approved assignment of BU = ML per section 5.2.1 and 5.5.1 of the BUS with a package size of 60mL for NDC 70644-215-30 and a package size of 120mL for NDC 70644-215-60.**
  - QUIC #202406 Arformoterol with Nebulizer  
**WG2 approved assignment of BU = ML per section 5.2.1 and 5.5.1 of the BUS with a package size of 60mL for NDC 70644-210-30 and a package size of 120mL for NDC 70644-210-60.**
- The **WG2 2023-2024 Accomplishments** presentation was given.

## Work Group 7 Manufacturer and Associated Trading Partner Transaction Standards

Ballots:

- **Ballot WG070016** – Enhancements to the to the Medical Rebate Data Submission Standard Implementation Guide Version 02.03 is considered a valid ballot having received the required 60+% of Consensus Group votes and 75+% approval rating. No comments were received. See

Letter Ballot Comment spreadsheet for the ballot results on the WG7 webpage. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.

#### Task Groups:

- The **Manufacturer Rebates Standard Task Group** continued analysis of the Telecommunication Standard VF6 DERFs impacting the Manufacturer Rebate Standard data elements and made updates for the next version of the implementation guide to reflect the changes within previously approved DERFs. The task group also addressed an inquiry from the WG1 Telecommunication FAQ Task Group regarding a flag to indicate a claim is not eligible for drug rebates from the manufacturer.
- The **Specialty Pharmacy Data Exchange Task Group** developed a proposed new definition for Benefit Type, evaluated needs for REMS-related elements, worked on determining a need for unique statuses and sub-statuses versus reusing values for the prescription journey and continued discussions of the statuses in the global status file.
- The **Medical Rebate Standard Task Group** did not meet this quarter.

#### New Business:

- The **WG7 2023-2024 Accomplishments** presentation was given.

### Work Group 9 Government Programs

#### Task Groups:

- The **Prescription Drug Monitoring Programs Task Group** continued monitoring state prescription monitoring program (PMP) activity and updated the State PMP Tracking Document which was approved by WG9 for publication on the NCPDP website.
- The **Medicare Part D Coordination of Benefits Other Health Insurance (COB-OHI) Data Sharing Task Group** discussed with the Centers for Medicare and Medicaid Services (CMS) enhancements to the Annual Full Replacement File. The task group also worked on the COB-OHI Industry Updates spreadsheet, identified out-of-sync issues between the Benefits Coordination and Recovery Center (BCRC) and Medicare Beneficiary Database (MBD) and began developing a plan for sending the Common Working File (CWF) Non-Group Health Plan (NGHP) COB-OHI records to Medicare Part D plans.
  - The **Government Funded Entitlement Programs Sub-Task Group** was disbanded.
  - The **Workers' Compensation Medicare Set-Aside Arrangement (WCMSA) Sub-Task Group** provided CMS with impediments to WCMSA investigation and requested assistance in the form of guidance. The sub-task group welcomed a new co-lead.
- The **Hospice Task Group** completed work on the Hospice Plan Savings Report and developed new fields and corresponding Reject Codes for Hospice Election Status Information Reporting (Nx) Transactions. The task group is changing their meeting day and time to bi-weekly on Thursdays at 11:00 a.m. CT.
- The **Medicare Financial Information Reporting (FIR) Task Group** discussed FIR errors being received by payers and worked with CMS to resolve an issue of missing 4Rx on FIR transactions. The task group is changing their meeting day and time to bi-weekly on Thursdays at 2:00 p.m. CT.
- The **Medicare FAQ Task Group** revised FAQ 2.83 to reinstate Benefit Stage Indicator value 51, which was approved for publication. The task group reviewed minor modifications made by the WG1 Telecommunication FAQ Task Group to an FAQ regarding Benefit Stage Amounts, which was approved for publication. Both FAQs will be published in the *Medicare Part D Frequently Asked Questions* on the NCPDP website. The task group also drafted a Benefit Stage Indicator DERF, which was approved by WG1 Telecommunication.
  - The **Insulin Pump Sub-Task Group** outlined how to use a Drug Utilization Review (DUR)

reject and DUR segment fields to communicate how insulin is being administered. The sub-task group conducted a straw poll in the WG1 Telecommunication FAQ Task Group to gather industry feedback on utilizing this solution for billing insulin to Medicare Part B and Medicare Part D.

- The **Medicare Prescription Payment Plan Program Task Group** reviewed *Medicare Prescription Payment Plan Program Draft Part Two Guidance* and submitted comments to CMS. The task group also reviewed *Medicare Prescription Payment Plan Program Final Part One Guidance* and the *Model Notice – Likely to Benefit Notice*. The task group drafted ten FAQs and supporting examples, which were approved for publication in the *Medicare Part D Frequently Asked Questions*. The task group drafted DERF 002013/Emergency ELC 000431 to update Approved Message Code 058, which was approved by WG1 Telecommunication.
- The **Maximum Fair Price Front-End Flow Task Group** worked with the WG9 Maximum Fair Price Back-End Processing Task Group to identify data fields that may be needed by the CMS Medicare Transaction Facilitator and sent correspondence to CMS regarding the data fields. The task group co-leads determined the Maximum Fair Price Front-End Flow and Back-End Processing Task Groups should be merged into a single task group. The task group requested and received approval to update the task group name and scope statement. The task group will be on hiatus until further work is requested by CMS.
- The **Maximum Fair Price Back-End Processing Task Group** worked with the WG9 Maximum Fair Price Front-End Flow Task Group to identify data fields that may be needed by the CMS Medicare Transaction Facilitator and sent correspondence to CMS regarding the data fields. The task group went on hiatus after the correspondence was submitted.
- The **Medicare Part D Section 111 Issues and Questions Task Group** reviewed the CMS Final Rule on Medicare Part D Section 111 Civil Monetary Penalties (CMPs) and the Top Ten Section 111 Group Health Plan (GHP) Reporting Errors presented by the CMS GHP CMP webinar. The task group is going on hiatus.
- The **Medicare Prescription Drug Event (PDE) Task Group** reviewed five CMS memos and submitted correspondence to CMS in response to the *Medicare Part D Redesign Program Instructions*. The task group created and submitted five new questions to CMS. The task group also reviewed DERF 002010/ECL 000428 related to Patient Residence Code values and suggested adding a value limitation indicating the Patient Residence Code value is not applicable to Medicare Part D.
- The **Medicaid Pharmacy Encounters Reporting Standard Task Group** completed their comparative analysis between the Medicaid Pharmacy Encounter Reporting Standard and the Telecommunication Standard VF6. The task group continued identifying changes needed in the Medicaid Pharmacy Encounter Reporting Standard Implementation Guide as a result of the analysis.
- The **Medicaid FAQ Task Group** reviewed and updated the *NDPDP WG9 Medicaid Questions and Answers* and began drafting a new FAQ about 340B provider validation to include in the document. The task group submitted questions to Health Resources and Services Administration (HRSA) on the ability to search 340B pharmacies using a pharmacy's National Provider Identifier (NPI).
- The **340B Task Group** did not meet this quarter.
- The **Medicare Standardized Fraud, Waste and Abuse Training Attestation Task Group** did not meet this quarter.

New Business:

- The **WG9 2023-2024 Accomplishments** presentation was given.

## Work Group 10 Professional Pharmacy Services

Task Groups:

- The **MTM and Pharmacist Clinical Services Task Group** is looking into all aspects of HL7® to equip the task group for the work of moving the Pharmacist eCare Plan to a new version to align with needed FHIR® and US Core versions. *NCPDP/HL7® Pharmacist eCare Plan and Fast Healthcare Interoperability for FHIR® Release 4* is published by HL7® and NCPDP.
- The **Pharmacogenomics Task Group** reviewed the NCPDP Precision Medicine Executive Summary Report. They also worked on the alignment of the existing task group scope with a new proposed scope, rationale for the reassessment of the scope having an emphasis on education and standardizing the approach and value proposition. These changes are being made to align with the NCPDP Strategic Initiative.
- The **WG14/WG10 Standardized Medication Profile Task Group** continued to work on two projects. The first project is writing a white paper or guidance document to assist application programming interface (API) vendors on how to access medication lists and perform medication reconciliation. The second project is building a standard FHIR® resource for a standardized medication profile (SMP) based off the *HL7®/NCPDP Standardized Medication Profile* white paper. The *NCPDP/HL7® Standardized Medication Profile (SMP) FHIR® Implementation Guide* is under development. The *SMP FHIR® Implementation Guide* is on target to be balloted by HL7® in September 2024.
- The **Identification of Social Determinants of Health Task Group** is on hiatus until further work is needed.
- The **WG10/WG11 Patient Consent Task Group** is reviewing and discussing potential use cases/scenarios. The task group has developed a scenario grid which contains five scenarios. They will continue looking for additional scenarios.
- The **mL White Paper Task Group** did not meet this quarter. A small group of key authors of the *NCPDP Recommendations for Standardizing Dosing in Metric Units (mL) on Prescription Container Labels of Oral Liquid Medications V2.0* met to discuss the merits of revising the white paper. The task group decided that an initial step in determining whether the white paper should be revised and/or other approaches pursued (e.g., educational outreach, letter to the editor summarizing key changes since the original paper) would be to repeat the survey of existing policies and practices regarding mL dosing in community pharmacies. The purpose would be to determine what impact the recommendations of the original survey may have had on policies and practices. The small group discussed the possibility of conducting a survey of actual practitioners (e.g., pharmacists) and whether to create a new survey aimed at assessing practices with ePrescribing/EHR vendors.

#### Other Reportables:

- **WG1 Pharmacy Services Billing Task Group, WG14 Consultant Pharmacist Interoperability Task Group** and **WG20 Health Equity Task Group**: Recaps for these task groups can be found in the WG10 download materials.

#### New Business:

- The **WG10 2023-2024 Accomplishments** presentation was given.
- The Work Group received a presentation from NCPDP Foundation Grant Recipient: RxLive on Outreach for Pharmacist Value Delivered.

## Work Group 11 ePrescribing & Related Transactions

#### DERFs Reviewed:

- DERF 002019 was approved as modified.

#### Ballots:

- **Ballot WG110095** – Enhancements to the NCPDP SCRIPT, Specialized and XML Implementation Guides Version 2024071 is considered a valid ballot having received the required 60+% of the Consensus Group and 75+% approval rating. One affirmative vote with comments was received. WG11 reviewed and

categorized the comments as persuasive and editorial. See Letter Ballot Comment spreadsheet for the ballot results and categorization of comments with reason on the WG11 webpage. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.

- **Ballot WG110096** – Enhancements to the Formulary and Benefit Standard V61 is considered a valid ballot having received the required 60+% of the Consensus Group and 75+% approval rating. No comments were received. See Letter Ballot Comment spreadsheet for the ballot results on the WG11 webpage. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.

#### Task Groups:

- The **ePrescribing Regulatory Task Group** did not meet this quarter.
- The **Formulary and Benefit Task Group** began working on the examples document for the Formulary and Benefit Standard V60. The task group continued working on transition guidance from V3.0 to V60.
- The **Implementation of Structured Sig Task Group** received approval to add additional values of chewable gel (Gummy) and Enema to the DoseUnitOfMeasure in the NCPDP NCI Subset maintained by the National Library of Medicine (NLM). The value of Kit was pended back to the task group for additional work. The task group also received an update from the NCPDP Foundation RxLive grant on the use of a large language model to convert text directions to the structured and codified sig elements.
- The **Pharmacy Product Locator Task Group** received approval for their updated task group scope. The task group continued to work on drafting a pharmacy product locator transaction for both a request and a response for the current use cases.
- The **Prior Authorization Workflow-to-Transactions Task Group** continued review of the prior authorization related guidance in the SCRIPT Implementation Guide. The task group also reviewed electronic prior authorization proposed rules from Minnesota and Maryland.
- The **RxChange Task Group** heard presentations from two NCPDP Foundation grants around the use of the RxChangeRequest and RxChangeResponse transactions and created action items stemming from the presentations.
- The **SCRIPT Implementation Recommendations Task Group** received approval for the addition of a new FAQ “For veterinarian prescriptions, can AlternateContact in the Non-Human/Patient elements be used to identify the animal’s owner?” to the *SCRIPT Implementation Recommendations* document. The task group also received approval to add an additional example of a NewRx from a veterinarian to the SCRIPT Standard Examples guide V2027071 and greater. See the *WG11\_SIR TG Recap\_Documentation\_Example* in the WG11 download materials for the details.
  - The **RxRenewal Review Sub-Task Group** received approval to publish “How are the Prescriber and PrescriberAgent and elements used on NCPDP transactions?” and “How should a covering prescriber be identified in an RxRenewalResponse transaction?” in the *SCRIPT Implementation Recommendations* document.
  - The **RxTransfer Sub-Task Group** reviewed questions received about the use of the transfer transactions.
- The **XML and JSON Task Group** brought forth DERF 002019 to add the elements of Race, Ethnicity and FinancialGuarantor to the grouping for PatientMandatoryAddress. They continued the work necessary to move the XML schema to the JSON format, which includes initial schema conversion, creation of a macro to correct issues found during the conversion, harmonization of datatypes used in the SCRIPT Standard with the Telecommunication Standard and began reviewing the implementation guides.

- The **WG10/WG11 Patient Consent Task Group** is reviewing and discussing potential use cases/scenarios. The task group has developed a scenario grid which contains five scenarios. They will continue looking for additional scenarios.
- The **WG14/WG11 LTPAC ePrescribing Task Group** received approval to publish four FAQs, “How can a sender indicate a special packaging requirement for patient compliance when transmitting an order to a pharmacy?”, “How should a sender indicate the patient requires special preparation instructions?”, “How can a sender indicate the prescription is specifically intended for discharge purposes?” and “In the context of LTPAC pharmacy managed workflow, how can pharmacy systems communicate both new and old RxReferenceNumber when renewing prescriptions?”. The task group continued working on a short-term and long-term solution for discharge prescriptions. Additionally, the task group reviewed FAQs for Topic 77 – Discharged Prescriptions and Topic 83 – Review of questions from SIR document. No modifications to these FAQs were recommended to the document during WG11.

#### Other Reportables:

- **WG1 Eligibility Verification Enhancements Task Group, WG1 Telecommunication Agility Next Generation (TANG) Task Group, WG19 Real-Time Prescription Benefit Task Group, WG19 API Task Group and WG19 REMS Workflow to Transactions Task Group:** Recaps for these task groups can be found in the WG11 download materials.
- Michael Rosenthal of Surescripts provided an update on the work being done in the **WG19 API Task Group** on an NCPDP API using OpenAPI.

#### New Business:

- The **WG11 2023-2024 Accomplishments** presentation was given.

## Work Group 14 Long Term and Post Acute Care (LTPAC)

#### Task Groups:

- The **LTPAC Billing Issues Task Group** worked on Telecommunication Standard VF6 editorial guidance, which was approved for publication.
- The **Consultant Pharmacist Interoperability Task Group** did not meet this quarter.
- The **WG14/WG11 LTPAC ePrescribing Task Group** received approval to publish four FAQs, “How can a sender indicate a special packaging requirement for patient compliance when transmitting an order to a pharmacy?”, “How should a sender indicate the patient requires special preparation instructions?”, “How can a sender indicate the prescription is specifically intended for discharge purposes?” and “In the context of LTPAC pharmacy managed workflow, how can pharmacy systems communicate both new and old RxReferenceNumber when renewing prescriptions?”. The task group continued working on a short-term and long-term solution for discharge prescriptions. Additionally, the task group reviewed FAQs for Topic 77 – Discharged Prescriptions and Topic 83 – Review of questions from SIR document. No modifications to these FAQs were recommended to the document during WG11.
- The **WG14/WG10 Standardized Medication Profile Task Group** continued to work on two projects. The first project is writing a white paper or guidance document to assist application programming interface (API) vendors on how to access medication lists and perform medication reconciliation. The second project is building a standard FHIR® resource for a standardized medication profile (SMP) based off the *HL7®/NCPDP Standardized Medication Profile* white paper. The *NCPDP/HL7® Standardized Medication Profile (SMP) FHIR® Implementation Guide* is under development. The *SMP FHIR® Implementation Guide* is on target to be balloted at HL7® in September 2024.

#### Other Reportables:

- **WG1 Eligibility Verification Task Group, WG9 Medicare FAQ Task Group, WG9 Hospice Task Group and WG1 Clinical and Safety Edits Task Group:** Recaps for these task groups can be found in the WG14 download materials.
- Gary Schoettmer of Stone Arch, LLC, provided an LTPAC industry update.

#### New Business:

- The **WG14 2023-2024 Accomplishments** presentation was given.

### Work Group 19 NCPDP Standards Coordination

#### Task Groups:

- The **Emergency Preparedness Task Group** did not meet this quarter. They will reconvene next quarter to review recommendations provided by the **WG19 COVID Post PHE Task Group**.
- The **Real-Time Prescription Benefit Standard Task Group** worked on an RTPB multi-threaded medication request transaction and decided to delay this addition. Following a review of a DERF to add new values for Reject Code and Approved Message Code for DUR limited fills, they recommended changes to the descriptions for the values so both could be used for RTPB's CoverageRestrictionCode and Coverage Restriction Code and are understandable to a prescriber recipient of an RTPB response. After reviewing a DERF to add a new Patient Pay Component Qualifier value, they decided the new value was not applicable to RTPB and should not be added to the list of values for RTPB for this field in the ECL. The task group started reviewing and updating the RTPB implementation guide to remove EDI content and include an enhancement to increase the diagnosis count to five on the RTPB request.
  - The **Consumer and Provider RTPB Standards Monitoring Sub-Task Group** did not meet this quarter.
  - The **Related RTPB Law Review Sub-Task Group** reviewed law activity for the states of Maryland, Illinois and Massachusetts. The state tracker was updated as needed.
- The **Digital Therapeutics Task Group** proposed a revision to their task group scope and goals. The scope and goals were pended back to the task group for further modifications.
- The **NDC Scarcity Task Group** finalized and emailed questions to GS1. Representatives from GS1 will join the task group call on June 19, 2024, to discuss the best way for partners to resolve any challenges a reformat of identifiers may present.
- The **COVID Post PHE Task Group** completed its review of the COVID/PHE specific guidance in the NCPDP Emergency Preparedness Guidance document. Recommendations from the task group have been forwarded to the **WG19 Emergency Preparedness Task Group** for consideration. They also discussed Reject 77 FAQ for United States Government (USG)-procured Paxlovid NDCs. No issues were identified in switching to the commercial NDCs.
- The **REMS Workflow to Transaction Task Group** continued development of REMSReversal transactions. The task group identified documents that need to be created and/or updated, including schemas for REMSReversal Request and Response transactions, implementation guide content and potential FAQs. A DERF has been drafted for these transactions, which will be presented at a future work group meeting. The task group will continue to follow the developments under HL7®'s CodeX FHIR® Accelerator of a new REMS process and workflow.
- The **API Task Group** worked on a presentation on APIs and OpenAPI Specification. The presentation included the following topics:
  - Scope and objective of task group
  - What is an API?
  - How is an API different than a transaction or data standard such as SCRIPT and Telecom?

- Doesn't NCPDP already have an API?
- Overview of Open API
- How does Open API specification complement JSON based standards?
- Demo of Open API
- The **Appropriate Use of Reject Code and Coverage Restriction Code Values Task Group** began reviewing use cases and understanding the decision-making process for payer selection of Reject Code (511-FB) values, as well as pharmacy interpretation and actions when reject codes are received. They looked at the over the counter (OTC) products without a prescription scenario, early refill scenarios and important factors for Pharmacy Benefit Managers (PBMs) when they select reject codes. They began reviewing previously identified categories and suggested new categories to group reject codes. The task group is currently defining parent and child categories with a goal to refine further as reject codes are organized into categories.

#### New Business:

- The **WG19 2023-2024 Accomplishments** presentation was given.
- The **USCDI Data Element Review Task Group** was formed to proactively review the United States Core Data for Interoperability (USCDI) recent versions to crosswalk NCPDP data elements and evaluate whether updates to NCPDP standards or submissions to the USCDI ONC New Data Element and Class (ONDEC) Submission System are needed.
- The **No RX OTC Transaction Processing Task Group** was formed to evaluate the impact on NCPDP standards of over the counter (OTC) products as they become an integral component of preventative and acute treatment options.

### Work Group 20 Coordination of Care and Innovation (CoCI)

#### Task Groups:

- The **Health Equity Task Group** completed documenting in their *Health Equity Data Element Inventory Tracker* whether the health equity concepts in United States Core Data for Interoperability (USCDI) have data elements in the NCPDP Data Dictionary, ECL and standards. They also documented whether the USCDI health equity concepts are in the joint *NCPDP/HL7® Pharmacist eCare Plan*.
- The **Admit, Discharge and Transfer (ADT) Notification for Pharmacy Task Group** began to work on a paper titled *Industry Guidance and Recommendations for Implementation of Admit, Discharge and Transfer Notifications for Pharmacy*. The paper is related to ADT notifications from hospitals to pharmacies.
- The **Pharmacy Technology Innovation (PTI) Task Group** discussed the purpose of their task group and developed a new scope statement. During WG20, the scope statement was approved.

#### New Business:

- The Work Group received a presentation and participated in a guided discussion on Healthy People 2030.
- The **WG20 2023-2024 Accomplishments** presentation was given.

### Work Group 45 External Standards Assessment and Implementation Guidance

#### Task Groups:

- The **Pharmacy and/or Combination ID Card Task Group** did not meet this quarter.
- The **834/835 FAQ Task Group** did not meet this quarter.
- The **Document Revisions Task Group** continued reviewing and updating the Claim Adjustment Reason Code (CARC) Mapping document. They also moved their call time to every other Thursday at 2:00 p.m. CT.

- The **DSMO Task Group** received no DSMO requests for review.
- The **Benefit Coverage Identification Task Group** reviewed the environmental scan from CAQH CORE and selected five subject matter experts to represent NCPDP in the upcoming CAQH CORE Eligibility and Benefit Task Group. They also provided requested feedback to CAQH CORE.
- The **Barcode Utilization Task Group** continued review of the white paper outline and is working with **WG19 NDC Scarcity Task Group** to see where harmonization can occur between the two task groups.
- The **X12 TR3 Comment Coordination Task Group** did not meet this quarter.

#### Other Reportables:

- Industry updates for WEDI, NCPDP SNIP, CAQH CORE, X12 and HL7® can be found in the WG45 download materials.

#### New Business:

- The **WG45 2023-2024 Accomplishments** presentation was given.

### MC Maintenance and Control

DERFs/ECLs: 16 new and two pended DERFs/ECLs were reviewed (see WG1, WG2 and WG11).

- DERF 001991/ECL 000418 was approved as modified.
- DERF 001992/ECL 000419 was approved as modified.
- DERF 002004/ECL 000422 was approved.
- DERF 002005/ECL 000423 was approved.
- DERF 002006/ECL 000424 was approved as modified.
- DERF 002007/ECL 000425 was approved.
- DERF 002008/Emerg. ECL 000426 was pended.
- DERF 002009/ECL 000427 was pended.
- DERF 002010/ECL 000428 was approved with modifications.
- DERF 002011/ECL 000429 was approved as modified.
- DERF 002012/Emerg. ECL 000430 was approved as modified.
- DERF 002013/Emerg. ECL 000431 was approved.
- DERF 002014/ECL 000432 was approved.
- DERF 002015/ECL 000433 was approved.
- DERF 002016/Emerg. ECL 000434 was withdrawn.
- DERF 002017/Emerg. ECL 000435 was pended.
- DERF 002018 was approved.
- DERF 002019 was approved as modified.

#### Task Groups:

- The **Education, Legislation and Regulations Task Group** reviewed and submitted NCPDP's response to the United States Core Data for Interoperability (USCDI) Draft Version 5/Level 2. The task group also began to review and develop comments on the 2024-2030 Draft Federal Health IT Strategic Plan. They decided no comments from NCPDP were needed on CMS-4201-F3, CMS-4205-F and Washington State Legislation for Health Care Benefit Managers Senate Bill 5213. The results of a straw poll during MC indicated NCPDP's response to 2024-2030 Federal Health IT Strategic Plan should be a general statement about NCPDP's work as it relates to the Plan.
  - The **USCDI Data Element Review Sub-Task Group** discussed the reason for its formation was to review the USCDI data elements to see where updates related to NCPDP could be applied. The sub-task group discussed their scope and the desire to become a full task

group under WG19. The sub-task group received approval to become a full task group under WG19.

- The **Management of Non-NCPDP Code Sets Task Group** reviewed and drafted edits to content in the *Telecommunication Version D and Above Questions, Answers and Editorial Updates* related to Route of Administration (995-E2) and SNOMED values. The task group also looked at the use of Route of Administration values within the SCRIPT Standard and potential flow from the inbound prescription through the pharmacy system and onto the claim transaction.

New Business:

- The attendees received recaps of each Work Group's activities.
- The **WGMC 2023-2024 Accomplishments** presentation was given.